Prepayments (CK93) - Nykredit Realkredit A/S
To the Nasdaq Copenhagen
Prepayments (CK93)
Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 23 December 2022 in the attached file.
Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/.
For further information about data format and contents, please refer to the Nasdaq website.
Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21.
Yours sincerely
Nykredit Realkredit A/S
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Storaktionærmeddelelse - Pharma Equity Group A/S23.4.2024 11:45:20 CEST | pressemeddelelse
Storaktionærmeddelelse - Pharma Equity Group A/S 23. april 2024 Selskabsmeddelelse nr. 14 Pharma Equity Group A/S har i henhold til kapitalmarkedslovens § 38 modtaget storaktionærmeddelelse om, at DMZ Holding ApS har erhvervet aktier i Pharma Equity Group A/S. Som følge heraf har DMZ Holding ApS øget deres ejerandel til over 5% i Pharma Equity Group A/S. For yderligere information, kontakt venligst: Thomas Kaas Selsø, Adm. direktør i Pharma Equity Group A/S, telefon: +45 4022 2114 Christian Vinding Thomsen, bestyrelsesformand i Pharma Equity Group A/S, telefon: +45 2622 7222 Om Pharma Equity Group A/S Pharma Equity Group er et børsnoteret selskab på Nasdaq Copenhagens hovedliste. Selskabets hovedfokus er på at fremme de forskellige lægemiddelkandidater i sit datterselskab, Reponex Pharmaceuticals A/S. Med et urokkeligt fokus på Health Care er Pharma Equity Groups primære mål at tilføre betydelig værdi til Reponex Pharmaceuticals' forskellige lægemiddelkandidater. Selskabet er forpligte
Planlagt suspension i Investeringsforeningen Nykredit Invest23.4.2024 11:43:25 CEST | pressemeddelelse
Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeBæredygtige AktierDK0060361046NYIBDAGlobale FokusaktierDK0060360824NYIGLAGlobale Fokusaktier Akk.DK0060038347NYIGFA Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit eller Christian Rye Holm, CRH@nykredit.dk. Med venlig hilsen Nykredit Portefølje Administration A/S Tage Fabrin-Brasted
Planlagt suspension i Investeringsforeningen Multi Manager Invest23.4.2024 11:36:31 CEST | pressemeddelelse
Det skal oplyses, at der grundet lokale børslukkedage i underliggende markeder vil være suspension af nedenstående afdelinger onsdag d. 1 maj 2024. Fund nameISINOrder book codeNye AktiemarkederDK0060316685MMINAMNye Aktiemarkeder Akk.DK0060316768MMINAAGlobale AktierDK0060447274MMIGAGlobale Aktier Akk.DK0060447357MMIGAAGlobale Value AktierDK0060918498MMIGLVAAKTGlobale Value Aktier Akk.DK0060918571MMIGLVAAKTAKK Eventuelle spørgsmål vedrørende denne meddelelse kan rettes til npa.pm@nykredit eller Christian Rye Holm, CRH@nykredit.dk. Med venlig hilsen Nykredit Portefølje Administration A/S Tage Fabrin-Brasted
Handelsinvest opdaterer prospektet23.4.2024 11:22:23 CEST | pressemeddelelse
Investeringsforeningen Handelsinvest Vestergade 8-16 8600 Silkeborg Tlf. 8989 2500 handelsinvest@jyskeinvest.dk www.handelsinvest.dk Nasdaq Copenhagen A/S Nikolaj Plads 6 1007 København K23. april 2024 Opdatering af prospektet i Handelsinvest Investeringsforeningen Handelsinvest har opdateret prospektet. Der er sket følgende opdateringer/ændringer: Opdatering af data på bestyrelsesmedlemmer.Tilføjelse af ”under overflytning” og ”under fusion” i de afdelingsspecifikke afsnit.Opdatering af investeringsstrategien i afdeling Nordamerika.Sproglige tilpasninger m.m. Det opdaterede prospekt kan findes på www.handelsinvest.dk Med venlig hilsen Lone Mørch Henrik Kragh Bestyrelsesformand Director
CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit23.4.2024 11:00:00 CEST | Press release
ZÜRICH, Switzerland, April 23, 2024 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced a presentation on its proprietary antibody-major histocompatibility complex (MHC) technology for the development of highly specific T-cell engagers (TCE) at the TCR-Based Therapies for Solid Tumors Summit, occurring April 23-25 in Boston, Massachusetts. The presentation will discuss how antibodies targeting tumor peptides on the MHC enable T-cells access to an untapped reservoir of intracellular tumor antigens and will highlight the M-gager® technology’s ability to leverage the potency, versatility and manufacturability of antibodies to revolutionize cancer immunotherapy. Presentation Details Title: Unlocking Tumor Eradication with Antibody-MHC T Cell Engagers Presenter: Leonardo Borras, Chief Scientific Officer Date: April 23, 2024 About CDR-Life CDR-Life is developing powerful T-cell engagers (TCE) to eradicate hard-to-treat solid tumors. Our integrated antibody-based TCE platform unlocks access to